On January 16, 2020 I-Mab ("I-Mab" or the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, reported the pricing of its initial public offering of 7,407,400 American Depositary Shares ("ADSs"), each ten (10) ADSs representing twenty-three (23) ordinary shares of the Company, par value US$0.0001 per share, at US$14.00 per ADS, assuming the underwriters do not exercise their option to purchase additional ADSs (Press release, I-Mab Biopharma, JAN 16, 2020, View Source [SID1234553310]). The ADSs will begin trading on January 17, 2020 on the Nasdaq Global Market under the symbol "IMAB."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company has granted the underwriters an option to purchase up to an additional 1,111,110 ADSs within 30 days from the date of the final prospectus at US$14.00 per ADS. The total gross proceeds of the offering are expected to be approximately US$ 103,703,600, assuming the underwriters do not exercise their option to purchase additional ADSs, or approximately US$ 119,259,140, if the underwriters choose to exercise their option to purchase additional ADSs in full.

Jefferies LLC and China International Capital Corporation Hong Kong Securities Limited are acting as joint book-running managers for this offering. China Renaissance Securities (Hong Kong) Limited and Huatai Securities (USA), Inc. are acting as lead managers for this offering.

The Company’s registration statement related to the offering has been filed with, and declared effective by, the U.S. Securities and Exchange Commission (the "SEC"). This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Copies of the prospectus related to the offering may be obtained from (i) Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388 or by e-mail at [email protected] or (ii) China International Capital Corporation Hong Kong Securities Limited, Attn: Rita Li, 29th One International Finance Center, One Harbour View Street, Central, Hong Kong, by telephone at (852) 2872-2000 or by e-mail at [email protected].